Zoetis Inc. announced first-quarter 2025 revenue of $2.2 billion, a 1% increase reported and 9% organic operational growth compared to Q1 2024. Adjusted net income for the quarter was $662 million, or $1.48 per diluted share, representing 6% organic operational growth.
The companion animal portfolio grew 9% operationally, driven by the Simparica franchise (19% operational growth to $367 million), Key Dermatology (10% operational growth to $387 million), and OA pain mAbs (15% operational growth to $147 million). Livestock also contributed with 7% organic operational growth.
The company maintained its full-year 2025 organic operational revenue guidance range of 6% to 8%. However, it updated its organic operational adjusted net income guidance to a range of 5% to 7%, reflecting the impact of enacted tariff-related cost impacts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.